IDH1 and neoplasm: An example is the IDH1‐mutant inhibitor ivosidenib (AG‐120), which has been approved by the US Food and Drug Administration for the treatment of refractory acute myeloid leukemia.[21] Recently, wild‐type IDH1 has been shown to play a role in tumor development and progression.